Table 1. Immunohistochemical analysis of all GBMs.

	Patient age < 45			Patient age ≥ 70
Gene	Positive	Total	%	Positive	Total	%
ALK	7	24	29.2*	1	24	4.2
cMET	6	117	5.1	2	108	1.9
EGFR	51	65	78.5	42	55	76.4
ERCC1	37	98	37.8	32	86	37.2
MGMT	7	81	8.6	3	60	5
PD-1	27	64	42.2	29	54	53.7
PD-L1	13	69	18.8	5	60	8.3
PGP	8	139	5.8	7	131	5.3
PR	11	143	7.7	7	134	5.2
PTEN	142	180	78.9	118	151	78.1
RRM1	65	136	47.8*	37	117	31.6
SPARCm	21	127	16.5	14	104	13.5
SPARCp	16	136	11.8	6	111	5.4
TLE3	39	108	36.1	36	100	36
TOP2A	90	148	60.8	69	130	53.1
TOPO1	96	167	57.5	73	148	49.3
TS	89	162	54.9	70	140	50
TUBB3	94	101	93.1*	69	90	76.7

^*indicates P value < 0.05.

List of abbreviations: ALK: anaplastic lymphoma kinase; cMET: MET or hepatocyte growth factor receptor; EGFR: epidermal growth factor receptor; ERCC1: excision repair cross-complementation group 1; MGMT: O⁶-methylguanine-DNA methyltransferase; PD-1: programmed cell death 1; PD-L1: programmed cell death ligand 1; PGP: P-glycoprotein; PR: progesterone receptor; PTEN: phosphatase and tensin homolog; RRM1: ribonucleotide reductase subunit M1; SPARC: secreted protein acidic and rich in cysteine; TLE3: transducing-like enhancer of split 3; TOP2A: topoisomerase II alpha; TOPO1: topoisomerase I; thymidylate synthase; TUBB3: class III beta-tubulin.